NASDAQ:IRWD
Ironwood Pharmaceuticals Inc.
Ironwood Pharmaceuticals Inc.'s revenue fell 15.7% in fiscal 2025 to $296.2M while operating margin rose to 33.3%. Free cash flow was $127.0M, 42.9% of revenue, and the diluted share count rose 1.8%.Summary generated from Ironwood Pharmaceuticals Inc.'s SEC filings. Latest annual report filed Feb 26, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$296.2M
Revenue growth−15.7%
Revenue, 5-yr CAGR−5.3%
Gross marginn/a
Operating margin33.3%
Net margin8.1%
ROICn/a
Return on equityn/a
Debt / equityn/a
Free cash flow$127.0M
FCF margin42.9%
Share count change+1.8%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 414 | 411 | 443 | 351 | 296 |
| Operating income | 232 | 250 | −945 | 93 | 99 |
| Net income | 528 | 175 | −1,002 | 1 | 24 |
| Free cash flow | 262 | 274 | 183 | 103 | 127 |
Recent filings
- 4Insider transaction report
Sep 17, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 6, 2026 - 8-KResults of operations and financial condition
Aug 6, 2026 - 4Insider transaction report
Jul 22, 2026 - 8-KDirector or officer change
Jun 18, 2026 - 8-KOther events
Jun 15, 2026 - 8-K/AAmended director or officer change
May 21, 2026 - 8-KDirector or officer change
May 13, 2026